Dr. Yelena Janjigian: The DESTINY-Gastric03 study confirms the therapeutic prospect of the T-DXd triple regimen in HER2-positive

Dr. Yelena Janjigian: The DESTINY-Gastric03 study confirms the therapeutic prospect of the T-DXd triple regimen in HER2-positive

The DESTINY-Gastric03 study (abstract number 14010), presented at the 2024 European Society for Medical Oncology (ESMO) Congress (September 13-17, Barcelona), evaluated the efficacy and safety of T-DXd combined with FP and anti-PD-1 as first-line treatment for adenocarcinoma of the esophagus, stomach, or gastroesophageal junction (GEJA). At the conference site, we specially invited the Principal Investigator, Dr. Yelena Janjigian from Memorial Sloan Kettering Cancer Center in the United States, to be interviewed by us on site.
ESMO 2024丨Dr. Junyuan Qi: Cutting Through the Fog, Promising Phase I Results for the New BCL-2 Inhibitor in R/R NHL and AML

ESMO 2024丨Dr. Junyuan Qi: Cutting Through the Fog, Promising Phase I Results for the New BCL-2 Inhibitor in R/R NHL and AML

From September 13th to 17th, the 2024 European Society for Medical Oncology (ESMO) Annual Meeting was held in Barcelona, Spain. As one of the world's top oncology conferences, it brought together experts and scholars from across the globe to share cutting-edge research findings and discuss future directions. At the session dedicated to hematologic malignancies, Dr. Junyuan Qi from the Institute of Hematology & Blood Diseases Hospital, Chinese Academy of Medical Sciences, presented the first-in-human study of the BCL-2 inhibitor TQB3909 in relapsed or refractory (R/R) non-Hodgkin lymphoma (NHL) and acute myeloid leukemia (AML), showing promising results. Hematology Frontier invited Professor Qi to provide an in-depth analysis of the study and discuss the future clinical applications and research directions for this novel BCL-2 inhibitor.
Dr. Peng Liu’s Team: A Promising Future as “Chemo-Free” Approaches Aim to Reshape First-Line Treatment Standards for Marginal Zone Lymphoma

Dr. Peng Liu’s Team: A Promising Future as “Chemo-Free” Approaches Aim to Reshape First-Line Treatment Standards for Marginal Zone Lymphoma

From September 13th to 17th, the 2024 European Society for Medical Oncology (ESMO) Annual Meeting was held in Barcelona, Spain. As one of the top international conferences in the oncology field, it brought together experts and scholars from around the world to share cutting-edge research findings and discuss future development directions. At this year's conference, a study led by Dr. Peng Liu's team from Zhongshan Hospital, Fudan University, was selected for a Mini Oral presentation, which was delivered on-site by Dr. Jiadai Xu. The study explored a chemotherapy-free first-line treatment approach for marginal zone lymphoma (MZL), with preliminary results proving promising. Hematology Frontier invited Dr. Xu for an in-depth discussion on the study and her expectations for the future of this treatment approach and research plans.
Dr. Aiming Pang: The “Tianjin Model” of Autologous Hematopoietic Stem Cell Transplantation for Acute Leukemia

Dr. Aiming Pang: The “Tianjin Model” of Autologous Hematopoietic Stem Cell Transplantation for Acute Leukemia

Autologous hematopoietic stem cell transplantation (ASCT) is a treatment option for adult acute leukemia in remission. Compared to allogeneic hematopoietic stem cell transplantation (allo-HSCT), ASCT has advantages such as no donor restrictions, absence of graft-versus-host disease (GVHD), and a lower transplant-related mortality rate. At the recent "4th Shanghai Symposium on the Clinical Application of Autologous Hematopoietic Stem Cell Transplantation," Dr. Aimang Pang from the Institute of Hematology & Blood Diseases Hospital, Chinese Academy of Medical Sciences, delivered an insightful presentation on the "Tianjin Model" for ASCT in treating acute leukemia. The highlights of the presentation are summarized here for our readers.
Dr. Ou Bai: Interpreting the BTKi Consensus for Indolent Lymphomas in Greater China region丨The 5th Tianjin International Lymphoma Academic Conference

Dr. Ou Bai: Interpreting the BTKi Consensus for Indolent Lymphomas in Greater China region丨The 5th Tianjin International Lymphoma Academic Conference

From September 6th to 8th, 2024, the 5th Tianjin International Lymphoma Academic Conference was successfully held. The conference featured 12 thematic sessions covering topics such as immunotherapy, translational research, and new drug development, creating a platform for promoting international academic exchange and collaboration. During the event, Hematology Frontier invited Dr. Ou Bai from The First Bethune Hospital of Jilin University to discuss the content of the Greater China region BTK Inhibitor Consensus on indolent lymphomas.
Dr. He Huang and Didier Blaise: Exploring Breakthroughs in Cellular Therapy from Sino-French Perspectives

Dr. He Huang and Didier Blaise: Exploring Breakthroughs in Cellular Therapy from Sino-French Perspectives

The 11th Sino-French Hematology Academic Conference, organized by the Chinese Medical Doctor Association, recently took place in Tianjin, drawing hundreds of leading experts and scholars in the field of hematology from around the world. During the conference, Hematology Frontier invited Dr. He Huang from The First Affiliated Hospital, Zhejiang University School of Medicine and Dr. Didier Blaise from the Hematology Institute of Aix-Marseille University in France to engage in a dialogue on the challenges and opportunities in new cellular therapies for hematologic malignancies. Here are the key insights from their conversation.